EDITAS MEDICINE, INC. Lessee, Operating Lease, Liability, to be Paid, Year Two
EDITAS MEDICINE, INC. (EDIT) had Lessee, Operating Lease, Liability, to be Paid, Year Two of $7.08 million as of 2025-12-31, per its 10-K filed 2026-03-09.
Financial Statements › Notes › Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity
us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo · last filed 2026-03-09
- 2025-12-31: Lessee, Operating Lease, Liability, to be Paid, Year Two $7.08M.
- 2024-12-31: Lessee, Operating Lease, Liability, to be Paid, Year Two $9.73M.
- 2023-12-31: Lessee, Operating Lease, Liability, to be Paid, Year Two $8.39M.
- 2022-12-31: Lessee, Operating Lease, Liability, to be Paid, Year Two $12.41M.
| Period end | Lessee, Operating Lease, Liability, to be Paid, Year Two |
|---|---|
| 2025-12-31 | $7.08M 10-K · filed 2026-03-09 |
| 2024-12-31 | $9.73M 10-K · filed 2025-03-05 |
| 2023-12-31 | $8.39M 10-K · filed 2024-02-28 |
| 2022-12-31 | $12.41M 10-K · filed 2023-02-22 |
| 2021-12-31 | $11.93M 10-K · filed 2022-02-24 |
| 2020-12-31 | $9.34M 10-K · filed 2021-02-26 |
| 2019-12-31 | $8.04M 10-K · filed 2020-02-26 |
| 2019-09-30 | $6.40M 10-Q · filed 2019-11-12 |
| 2019-06-30 | $5.62M 10-Q · filed 2019-08-07 |
| 2019-03-31 | $5.62M 10-Q · filed 2019-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |